Orchard Software Partners With Luxor Scientific to Expand Testing Services
CARMEL, Ind., May 8, 2024 /PRNewswire/ -- Orchard Software is pleased to announce its collaborative test-expansion partnership with Luxor Scientific Medical Laboratories. Luxor Scientific has grown r
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today
Orchard Software Announces New Electronic Support for Antimicrobial Stewardship
CARMEL, Ind., April 4, 2024 /PRNewswire/ -- Today, Orchard Software announced the availability of Antimicrobial Use and Resistance (AUR) reporting to the National Healthcare Safety Network (NHSN), wh
Orchard Therapeutics Announces Launch Plans For Lenmeldy - Quick Facts
Orchard Therapeutics Receives FDA Approval of Lenmeldy (Atidarsagene Autotemcel), the Only Therapy for Eligible Children With Early-onset Metachromatic Leukodystrophy in the U.S.
Orchard Therapeutics today announced the U.S. Food and Drug Administration (FDA) has approved Lenmeldy (atidarsagene autotemcel), formerly known as OTL-200, for the treatment of children with pre-symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ)—collectively referred to as early-onset—metachromatic leukodystrophy (MLD).
ORI Capital Raises $260 Million for Second Life Sciences Fund
- Fundraise closed above its original target, reflecting strong interest from institutional, strategic and high net worth investors globally ORI Capital today announced the final close of its second fund, ORI Fund II
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient's own hematopoietic stem cells HURCULES study to
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
BOSTON and LONDON, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients
Kyowa Kirin Acquires All Outstanding Shares of Orchard Therapeutics
Japanese pharmaceutical and biotechnology company Kyowa Kirin (TYO:4151) wholly acquired all the outstanding shares of Orchard Therapeutics, according to a Thursday release. Kyowa Kirin acquired a tot
Orchard Therapeutics Reached An Agreement With The Beneluxa Initiative On Pharmaceutical Policy (Beneluxa) Enabling Reimbursed Access To Libmeldy= (Atidarsagene Autotemcel) Approved For The Treatment Of Early-onset Metachromatic Leukodystrophy (MLD)
Orchard Therapeutics Reached An Agreement With The Beneluxa Initiative On Pharmaceutical Policy (Beneluxa) Enabling Reimbursed Access To Libmeldy= (Atidarsagene Autotemcel) Approved For The Treatment
Orchard Therapeutics Announces Agreement With the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy
Orchard Therapeutics Announces Board Reshuffle Following Transaction
Orchard Therapeutics' Shareholder Rights Altered Post-Acquisition
Orchard Therapeutics ADSs Delisting From Nasdaq
Orchard Therapeutics Acquired by Kyowa Kirin
Orchard Therapeutics Ends Key Financial Agreement Post-Transaction
News On Orchard Therapeutics PLC (ORTX) Now Under 4151.TO
News On Orchard Therapeutics PLC (ORTX) Now Under 4151.TO
Orchard Therapeutics Becomes Wholly-Owned Subsidiary of Kyowa Kirin >ORTX
Orchard Therapeutics Becomes Wholly-Owned Subsidiary of Kyowa Kirin >ORTX
Kyowa Kirin: Acquisition Was Completed Wednesday >ORTX
Kyowa Kirin: Acquisition Was Completed Wednesday >ORTX
Kyowa Kirin Successfully Completes Acquisition Of Orchard Therapeutics, A Global Gene Therapy Leader For Rare Diseases ORTX
Kyowa Kirin Successfully Completes Acquisition Of Orchard Therapeutics, A Global Gene Therapy Leader For Rare Diseases ORTX
No Data